Patent application number | Description | Published |
20090005378 | PYRROLO-PYRIDINE KINASE MODULATORS - The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity. | 01-01-2009 |
20090156594 | HETEROCYCLIC KINASE MODULATORS - The present disclosure provides heterocyclic protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity. | 06-18-2009 |
20090258855 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS - The present disclosure provides bicyclic triazole protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity. | 10-15-2009 |
20100120739 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS - The present disclosure relates to triazolopyridazine protein kinase modulators of Formula (I), methods of using these compounds to treat diseases mediated by kinase activity. | 05-13-2010 |
20100179190 | BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS - The present invention provides novel bicyclic pyrazolo kinase modulators and methods of using the novel bicyclic pyrazolo kinase modulators to treat diseases mediated by kinase activity. | 07-15-2010 |
20130012513 | HEDGEHOG INHIBITORS - Described herein are compounds, pharmaceutical compositions and methods for the inhibition of Hedgehog signaling. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human and veterinary disease and disorders. | 01-10-2013 |
20130040983 | RAF KINASE INHIBITORS - Described herein are compounds, pharmaceutical compositions and methods for the inhibition of RAF kinae mediated signaling. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human disease and disorders. | 02-14-2013 |
20140205537 | LRRK2 INHIBITORS - Provided herein are compounds that inhibit or partially inhibit the activity of leucine rich repeat kinases. Also provided herein are methods of treatment of CNS disorders comprising administration of inhibitors of leucine rich repeat kinases. | 07-24-2014 |
20140221374 | RAF KINASE INHIBITORS - Described herein are compounds, pharmaceutical compositions and methods for the inhibition of RAF kinase mediated signaling. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human disease and disorders. | 08-07-2014 |